Alcohol Disrupted Eye Tracking in Ways That Cannabis Did Not ↗
Alcohol impaired smooth eye tracking at multiple doses. Cannabis produced no measurable effect on the same visual tracking tasks in experienced users.
Explore published research on driving, including study methods and limitations.
Alcohol impaired smooth eye tracking at multiple doses. Cannabis produced no measurable effect on the same visual tracking tasks in experienced users.
Among 600 drivers killed in single-vehicle crashes, alcohol was detected in 79.3% at high levels. THC was found in only 7.8%, and most drug-positive drivers also had high blood alcohol.
Five cannabis-naive volunteers tested positive for THC in blood and urine after 30 minutes of passive exposure to cannabis smoke in a closed car.
At controlled doses, alcohol and marijuana produced identical perceived impairment and comparable deficits on memory and processing speed tests. Neither affected reaction time.
THC was detectable in saliva (64%) and forehead sweat (73%) of cannabis-positive injured drivers, offering non-invasive alternatives that better indicate recent use than urine testing.
THCV-COOH, a urinary metabolite unique to natural marijuana, reliably distinguished marijuana use from prescription Marinol use in a controlled crossover study.
European review found illicit drug prevalence of 1-5% among drivers, with cannabis among the top substances of concern. Discussed evolving detection technologies and zero-tolerance versus impairment-based legal approaches.
Two studies in an unventilated van found passive cannabis smoke exposure only caused positive oral fluid tests when samples were collected in the smoky environment. Samples collected outside were all negative.
Review of oral fluid drug testing found THC detection is complicated by depot effects from mouth absorption after smoking, temporarily inflating concentrations above blood-comparable levels.
Controlled study of 20 cannabis users found impairment began at 2-5 ng/ml serum THC, with 75-90% impaired at 5-10 ng/ml and 100% above 30 ng/ml, providing a framework for driving limits.
In 24 non-daily users, cognitive and motor impairment increased linearly with THC dose (up to 69 mg), but some individuals showed no motor impairment even at blood THC above 40 ng/mL.
After smoking the same THC dose, occasional cannabis users were impaired on 3 of 4 cognitive tasks while heavy users showed impairment only on motor inhibition at high blood levels, demonstrating functional tolerance.
Cannabis impaired automatic driving functions and prompted compensatory behavior, while alcohol impaired complex tasks without compensation. Combining both eliminated compensation and multiplied impairment.
Dividing saliva THC concentration by a regression coefficient provided acceptable population-level estimates of blood THC, useful for roadside surveys, though inaccurate when fewer than 15% had high blood levels.
In a simulator, high-dose cannabis impaired multiple driving measures while alcohol at moderate doses had fewer effects. Cannabis decreased speed while alcohol slightly increased it, with no synergistic effects at tested doses.
Review compared blood, urine, and oral fluid testing for cannabis-impaired driving, finding each has different strengths and no matrix perfectly predicts impairment.
Comprehensive review found recreational cannabis adverse effects were generally minor, with overall harms appearing less serious than alcohol, though vulnerable individuals faced greater risks.
Among 609 traffic crash victims in Brazil, 13.3% of drivers tested positive for cannabis, and alcohol dependence increased odds of any substance-related crash 5.2-fold.
After 3 hours in Dutch coffee shops, 50% of non-smoking volunteers tested above THC screening cut-offs in oral fluid, but the metabolite THC-COOH distinguished passive from active exposure.
Meta-analysis of 9 studies found cannabis nearly doubles motor vehicle crash risk (OR 1.92), with higher risk for fatal crashes.
Field sobriety tests poorly detected cannabis impairment in 20 heavy users, though the Drager oral fluid device reliably detected THC presence.
On-road driving study showed medicinal THC impaired driving in both occasional and heavy users beyond the 0.05% BAC threshold, but field sobriety tests missed it.
California roadside survey found 8.5% of weekend nighttime drivers tested THC-positive, ranging from 4.3% to 18.3% by jurisdiction, with rates increasing since 2007.
Oral fluid testing detected all drug types found in blood among 100 suspected drug drivers, offering a faster alternative to urine collection.
Brain imaging showed cannabis disrupted attention and executive control networks while increasing self-focused brain activity, even at low blood THC levels.
THC blood levels in suspected impaired drivers in Norway rose 58% from 2000 to 2010, far outpacing increases in alcohol or amphetamine levels in similar drivers.
A specific AKT1 gene variant determined whether THC impaired psychomotor control, with carriers showing increased errors and reduced brain activation in a motor control region.
Post-marketing data from the UK, Germany, and Spain confirmed THC/CBD spray effectiveness for MS spasticity (41% response rate) with no abuse signal or driving impairment.
Review of oral fluid cannabis testing found THC can exceed 1,000 micrograms/L after smoking, with detection windows varying by route, dose, and use history.
Pilot study found Sativex patients had oral fluid THC over 5,356 ng/mL shortly after dosing, remaining detectable for 2+ hours, with primary roadside test often giving false negatives.
Analysis of 2,142 drug evaluations found field sobriety tests detected impairment across all drug categories including cannabis, with different patterns for each drug class.
Review of data from 1,000+ MS patients found Sativex did not cause cognitive decline at 12 months, did not impair driving, and maintained effectiveness at lower real-world doses.
Colorado saw a significant increase in marijuana-positive drivers in fatal crashes after commercial medical marijuana expanded in 2009, while 34 comparison states showed no similar change.
Analysis of 72,053 high school seniors found simultaneous use of alcohol and marijuana was associated with the highest rates of unsafe driving, exceeding concurrent or single-substance use.
Population survey of 4,014 Ontario adults found those screening positive for ADHD reported more substance use but no more collisions or driving after drinking or cannabis use.
Analysis of 1,074 crash-injured drivers in South Australia found alcohol was the dominant substance, and over a third of cannabis-positive drivers were also heavily intoxicated with alcohol.
After smoking identical cannabis, occasional users showed significantly more psychomotor impairment than frequent users, demonstrating tolerance to performance-impairing effects.
US fatal crash data (1991-2008) showed combined alcohol and THC increased unsafe driving odds beyond either substance alone, with prevalence rising five-fold over the period.
Among 772 college freshmen, moderate drinkers who also used marijuana had significantly more blackouts, injuries, and DUIs than moderate drinkers who did not use marijuana.
Mouse study found synthetic cannabinoid JWH-018 impaired sensory function at very low doses and caused convulsions at high doses, effects not seen with equivalent THC doses.
Belgium's switch from urine to oral fluid roadside drug testing cut the false positive rate from 17% to 8%, though cannabis confirmation rates also changed.
A clinical review found cannabinoids offer modest benefits for nausea and inconsistent benefits for pain, while risks include cognitive impairment, driving accidents, dependence, and psychosis.
A systematic review of 21 studies found that biomarker patterns in urine, blood, oral fluid, and hair can distinguish passive cannabis exposure from active use, though extreme exposure can trigger positive tests.
Cannabis impairs driving by increasing lane weaving and following distance, with cognitive deficits lasting weeks after cessation and combined alcohol-cannabis use worsening impairment.
Analysis of 2,638 driver fatalities found cannabis and amphetamines elevated crash risk, while prescription opioids, benzodiazepines, and antidepressants alone did not significantly increase crash responsibility.
Analysis of 302 confirmed cannabis-impaired drivers found the finger-to-nose test was the best single indicator of impairment, and combining four behavioral tests achieved over 96% accuracy, while blood THC cutoffs showed limited value.
Review of THC detection methods across blood, urine, saliva, and hair highlights growing challenges for drug testing programs as legal medical cannabis products like Sativex produce positive results.
Controlled trial shows smoking and vaping deliver cannabis identically to blood, identifies potential biomarkers for recent use, and proposes detection cutoffs under 8 hours.
Among underage drinkers in an ER sample, marijuana use more than doubled the odds of driving after drinking for females and significantly increased risk for males.
Review of 36 studies confirms cannabis impairs multiple driving functions and doubles or triples crash risk, with cannabis-alcohol combination increasing injury risk nearly 11-fold.
Trauma patients testing positive for substances including cannabis had 3.2 times the odds of having multiple previous traumas, suggesting substance use is a marker for recurring injury.
Controlled study showing oral cannabis caused 6.4x higher impairment odds on sobriety tests in occasional users, with tolerance in frequent users, highlighting the delayed impairment risk of edibles.
Analysis of 4,294 fatal crashes in California found cannabis-positive drivers were 1.89x more likely to be crash-responsible at zero BAC and 3.42x more likely at very low BAC.
Methodological analysis explaining why two studies using the same crash databases reached opposite conclusions about marijuana and fatal accident risk, highlighting critical database limitations.
Controlled study found smoked/vaporized cannabis produced higher peak THC in saliva, while edibles created wider metabolite detection windows, with minor cannabinoids showing promise as markers of recent use.
Controlled study found oral cannabis produced much lower blood THC levels than inhalation, with effects peaking at 1.5-3 hours and lasting 6-8 hours, complicating drug testing for edible users.
Review found no increase in accidents from Sativex spray in MS patients, with most reporting improved driving after treatment, though blood THC may exceed legal limits in some countries.
Major review documented US increases in cannabis potency, use disorders, ER visits, and fatal crashes alongside growing perception of harmlessness, while medical marijuana laws showed no effect on adolescent use.
Analysis of 4,596 drivers found oral fluid THC tests were 79% sensitive and 98% specific for detecting cannabis use, but poorly predicted actual blood THC levels.
Case report documented driving impairment from synthetic cannabinoid 5F-ADB, detected at 26.37 ng/mL in blood with no other drugs present. One of the first cases conclusively linking synthetic cannabinoids to impaired driving.
A controlled trial found cannabis with equal CBD and THC impaired driving and cognition as much as THC-only cannabis, with CBD actually worsening some cognitive tasks, possibly by increasing THC blood levels.
A prospective study of 3,005 injured drivers found no crash risk increase with THC below 5 ng/mL and only a non-significant increase above, compared to sixfold increase for alcohol above 0.08%.
A review of 52+ studies found cannabis impairs driving but blood THC levels do not reliably predict impairment, creating a fundamental challenge for per se driving laws.
Systematic review of 15 studies finds no current roadside oral fluid test for cannabis meets the 80% accuracy standard, though devices detecting lower THC levels showed better performance.
Roadside testing of 2,355 Washington drivers found daytime THC-positive rates tripled after recreational sales opened, while risk perceptions and self-reported use remained unchanged.
Review finds neither per se THC blood limits nor field sobriety tests reliably detect cannabis-impaired driving, arguing for general impairment detection strategies instead of substance-specific approaches.
Lancet review finds cannabis legalization associated with increased use and road crash concerns, warns commercial cannabis industries may resist effective regulation like alcohol and tobacco, and outlines harm-minimizing policy approaches.
Analysis of 42 years of US fatal crash data finds little evidence that April 20th cannabis celebrations increase drivers involved in fatal crashes when compared against appropriate control periods.
Spain's national roadside testing of 180,000 drivers found THC in 80% of drug-positive tests, with half of THC-positive drivers also positive for cocaine or amphetamines, especially at lower THC levels.
Pilot RCT found computer-based screening and brief counseling in pediatric visits reduced teen cannabis use by 38% and riding with impaired drivers by 42% over 12 months.
Controlled study shows breath THC testing reliably detects cannabis use during the 3-hour impairment window, with kinetics closely tracking blood levels.
THC impaired standard cognitive tests but brief phone-based equivalents mostly failed to detect the impairment, casting doubt on phone apps as cannabis sobriety tests.
Oral fluid THC testing was good at detecting any blood THC, but less reliable at predicting specific blood concentrations relevant to impairment.
A Washington roadside survey found drivers with children were far less likely to drink but just as likely to test positive for THC.
Among young injured drivers in Arizona, 30% tested positive for THC and 19% for alcohol, with substance users less likely to use safety equipment.
Ten-year Canadian study found chronic and increasing cannabis users were most likely to drive impaired as young adults.
Analysis of 772 fatally injured drivers in Norway found cannabis impairment linked specifically to driving without a valid license, unlike alcohol which was linked to speeding and no seatbelt.
Interviews with impaired driving offenders found widespread belief that driving stoned is safer than driving drunk, with optimism bias about personal crash risk.
JAMA trial with actual on-road driving found THC impaired lane-keeping for up to 100 minutes but not at 4 hours, while CBD had no measurable effect.
South Australian data show illicit drugs now detected in more crash victims than alcohol, with drug-positive rates rising as alcohol rates fell over a decade.
A small crossover trial found cannabis-intoxicated drivers showed decreased theta brain waves that correlated with worse lane-keeping in a simulator, suggesting EEG patterns could help identify cannabis impairment.
A Canadian survey of 14,520 high school students found a strong dose-response relationship between perceived cannabis risk and impaired driving, with low-risk perceivers far more likely to drive or ride high.
Non-intoxicated heavy cannabis users showed impaired simulated driving, but only those who started regular use before age 16. Late-onset users performed similarly to non-using controls.
A study of 5,000 injured Australian drivers found THC modestly increased crash culpability (OR 1.9) vs. methamphetamine (OR 19), with drug combinations dramatically amplifying risk.
Mouse study found synthetic cannabinoids combined with alcohol caused worse motor impairment than either alone, mediated by reduced glutamate signaling in the cerebellum via CB1 receptors.
Study of 65 frequent concentrate users found dabbing impaired arm speed for at least 1 hour and balance immediately, with motor impairment poorly correlated to blood THC levels.
Survey of 17,405 cannabis users found men using both medically and recreationally had 40% probability of driving high, versus 20% for women using medically only.
Driving simulator study found each unit increase in blood THC impaired task completion, accuracy, and lane-keeping during divided-attention tasks, with low alcohol adding further impairment.
Time-series analysis found Uruguay cannabis legalization associated with 52% increase in car driver fatalities, concentrated in urban Montevideo, with no effect on motorcyclists.
Study of 20 drivers found cannabis impaired visual acuity, contrast sensitivity, and depth perception, with visual deficits directly correlated with worse driving performance.
Systematic review found frequent cannabis users can exceed legal THC driving limits (2 or 5 ng/mL) after days of abstinence, challenging per se laws.
Controlled study found oral cannabis at 25-50 mg THC markedly impaired cognition in infrequent users, with effects delayed 30-60 min and peaking at 1.5-3 hours.
Controlled study of cannabis brownies found blood THC peaked at 1.5-2 hours, women had higher concentrations, and oral fluid testing reflected oral deposition, not blood levels.
Officers at outdoor concerts had measurable airborne THC exposure and 34% had a THC metabolite in urine, but all levels were far below impairment or drug-screening thresholds.
A systematic review found moderate evidence that THC reduces speed, headway distance, and reaction time while increasing lane variability in young drivers ages 15-24.
In a simulated driving study of 14 people, legal THC blood limits failed to correctly predict impairment. Nearly half exceeded the limit without being impaired, while over half were impaired when THC levels had dropped below the cutoff.
A study of 921 driver fatalities in Ontario found more tested positive for THC (251) than alcohol (241). THC-positive crashes were spread throughout the week and more often involved multiple vehicles.
Despite growing legalization, key questions about cannabis and driving remain unanswered, including the dose-response relationship, tolerance effects, edible impairment timelines, and differences between medical and recreational users.
A simulator study of 85 adults found occasional cannabis users showed significant driving impairment after smoking, while daily users showed a non-significant trend. Daily users had 5-6 times higher blood THC but drove slower as a compensatory behavior.
Almost all cannabis driving research uses ~6% THC products, while consumers buy flower at 20%+ THC and concentrates above 60%. This gap means the true impact of modern cannabis on driving may be significantly underestimated.
In a small simulator study, cannabis users who felt stimulated showed less driving impairment than those who felt stoned. Subjective experience predicted steering behavior, while actual lane control was predicted by cannabis dose.
Analysis of over 239,000 traffic-injury emergency visits in Ontario and Alberta found no increase in driver injuries after Canada legalized cannabis in October 2018, including no increase among youth drivers.
One in ten licensed Ontario high school students reported driving within an hour of using cannabis. Cannabis dependence was the strongest predictor (OR 12.7), followed by low perceived risk and pro-legalization attitudes.
A Canadian survey of 5,630 emerging adults found both habitual and casual cannabis users had about 1.8 times the odds of traffic violations, with the association strongest among younger users and those not using other drugs.
A third of young cannabis-using Ontario drivers reported driving high, with 42% planning to do so again. Past behavior, low moral awareness, and low perceived danger were the strongest predictors of future cannabis-impaired driving.
Scoping review of seven controlled trials found medical cannabis patients showed THC dose-dependent cognitive decline that fully resolved within 4 hours in every study.
Study of 191 cannabis users found blood THC per se limits performed poorly at detecting recent use, with oral fluid THC at 10 ng/mL showing the best but still imperfect performance.
Controlled trial of 191 cannabis users found oral fluid THC at 10 ng/mL was the best biomarker for detecting use within 3 hours, outperforming blood measures and showing less bias against frequent users.
Study of 367 college students found using alcohol, marijuana, and nicotine together was associated with over 10 times the odds of impaired driving compared to alcohol use alone.
Cohort study of 29,153 medical cannabis patients found authorization associated with a small but significant increase in motor vehicle crash-related healthcare visits, primarily emergency department visits.
A psychophysiology study of 50 young adults found that driving-related cannabis risk messages generated the strongest attention, arousal, and emotional engagement compared to messages about cognition or health.
A meta-analysis of 80 studies found THC impairs driving-related skills at peak effect, with impairment from inhaled cannabis generally resolving within 3-5 hours. Researchers recommended waiting at least 5 hours before driving.
A survey of 1,813 Ontario adults found most people recognize cannabis-impaired driving risks, but male frequent cannabis users were the most likely to dismiss these risks, and safety concerns predicted actual driving behavior more than fear of legal consequences.
Analysis of 1,110 digital cannabis assessments found higher problem scores and polysubstance use predicted driving after cannabis use, with the tool costing under a dollar per use.
Daily diary study finds simultaneous alcohol-marijuana use increases riding with impaired drivers, while non-simultaneous use of both substances most increases driving after use.
Review finds cannabis impairs driving skills but blood THC levels are unreliable impairment markers, arguing that cannabis driving policy has outpaced the science.
Australian policy analysis finds zero-tolerance THC driving laws harm medicinal cannabis patients without evidence of greater road risk compared to other impairing prescription drugs.
Systematic review of 28 studies finds packaging warnings, roadside testing, and motivational interviewing most effective for preventing drugged driving, while legal sanctions show little impact.
Small crossover study finds specific EEG changes during cannabis intoxication, including decreased theta power and altered brain connectivity, suggesting potential for objective intoxication detection.
National survey of 128,205 adults found 4.5% drove under the influence of cannabis, with rates climbing sharply among daily users (57% predicted probability) and those with cannabis use disorder (63.8%).
Survey of 2,084 adults found that driving-while-high behavior is driven by a system of beliefs including attitudes, social norms, and perceived control, with intention being a stronger predictor than willingness alone.
Controlled study found standard field sobriety tests failed to detect cannabis impairment, while a novel app (DRUID) reliably identified it. Blood THC levels returned to baseline before impairment resolved.
Pilot trial of 77 college cannabis users found that personalized feedback plus text messaging significantly increased perceptions of dangerousness of driving after cannabis use at 3 months.
After Washington legalized recreational cannabis, THC-positive drivers in fatal crashes more than doubled (9.3% to 19.1%), with high-concentration THC drivers increasing nearly five-fold.
Controlled study found the synthetic cannabinoid JWH-018 at a relatively low dose significantly impaired motor coordination, attention, memory, and response speed in 24 cannabis-experienced adults.
Analysis of nearly 3,000 suspected impaired drivers in Quebec (2014-2018) found cannabis in 48% of cases, methamphetamine in 54%, and polydrug use in 79%, establishing a pre-legalization baseline.
Multi-state ecologic study found recreational cannabis legalization was associated with a 15% increase in fatal motor vehicle collisions and 16% increase in traffic deaths.
Small study of 16 older adults found chronic cannabis users had higher fall risk, worse balance, and slower walking speed than matched non-users, though cognitive function was similar.
An expert panel rated state monopoly as the most effective cannabis policy for reducing youth use, excessive use, and impaired driving, while noting almost no direct evidence exists for most policies.
A review of Canada's cannabis legalization finds mixed public health impacts: use increased in some groups, smoking declined, hospitalizations showed mixed results, and impaired driving prevalence was stable.
A survey across three U.S. states found earlier cannabis use onset, male sex, and living in a legal state were linked to more cannabis-impaired driving and more positive safety perceptions.
A driving study found self-reported cannabis effects predicted driving performance beyond THC dose, but which feelings mattered varied between studies, with "stoned" being the most consistent.
An Argentine ER study found alcohol increased road traffic injury risk nearly 7-fold, with combined alcohol-cannabis use showing similar risk, particularly among those under 30.
National survey found cannabis users in legal states were 59-61% less likely to report driving within 3 hours of getting high compared to users in non-legal states.
A controlled trial found combining alcohol and cannabis increased driving impairment beyond either substance alone, and users were unaware of the added impairment.
Portable brain imaging with machine learning detected THC impairment with 76% accuracy and only 10% false positives, outperforming field sobriety tests.
Colorado county-level analysis found dispensary openings increased cannabis-related hospitalizations but not traffic crash rates.
Among 910 young Canadian adults who drive after cannabis use, four distinct profiles emerged, from well-adjusted youth to those with generalized risky behavior and high distress.
Frequent cannabis users showed peak psychomotor impairment immediately after smoking but recovered significantly within one hour, replicated across two studies.
In Uruguay, registered cannabis self-cultivators were associated with more traffic crashes, while pharmacy purchases and cannabis clubs showed no consistent link.
Researchers created a practical clinical framework for assessing cannabis-related impairment risk in patients, designed especially for those with safety-sensitive work duties.
RCT of 191 regular cannabis users found simulated driving impairment lasted up to 3.5 hours, but 69% felt ready to drive at 1.5 hours. THC content and use history did not predict impairment level.
Crossover RCT found oral CBD up to 1,500 mg did not impair simulated driving or cognition compared to placebo, though high-dose CBD persisted in blood for over 4 weeks.
Meta-analysis of 28 studies found blood and saliva THC levels are poor predictors of driving impairment, with negligible to weak correlations that disappear entirely in regular cannabis users.
In 515 roadside drug tests after oral CBD up to 1,500 mg, zero false-positive THC results were observed, confirming pure CBD does not trigger standard cannabis drug tests.
Driving study found occasional cannabis users had 3.7x higher lane departure risk during distracted driving after smoking, while daily users compensated by driving slower.
Experimental study found both alcohol and cannabis impaired visual function, but only the higher alcohol dose (450 ml wine) significantly worsened driving simulator performance.
Meta-analysis of 18,000+ paired samples found oral fluid THC tests detect recent cannabis use well but are unreliable for predicting whether blood THC exceeds legal driving limits.
Study of 189 DUI-convicted drivers found those with alcohol interlock devices increased cannabis use, and this substitution persisted after device removal.
Meta-analysis of 57 driving studies found cannabis impairs lane control at levels comparable to low blood alcohol, with cannabis plus alcohol producing the worst impairment.
Pilot trial of 97 college students found mobile phone intervention with personalized feedback and text messaging reduced driving after cannabis use over 3 months.
A portable potency tester combined with real-time tracking created the first practical standard THC unit measure — higher milligram doses correlated with greater intoxication.
Controlled trial of 28 young adults found cannabis mainly affects mood and subjective experience while alcohol primarily impairs cognition and motor performance. Combined effects were additive at most.
Systematic review of 65 studies found medical cannabis legalization associated with fewer fatal crashes while recreational legalization associated with more, with both increasing cannabis-positive driver tests.
Survey of 1,063 Australian medical cannabis users found 28% reported driving under the influence, with half typically driving within 6 hours of use and low perception of impairment.
Survey of 424 cannabis users found frequent users waited less before driving and perceived less impairment, with even those who acknowledged impairment not waiting longer.
Qualitative study found young people ride with cannabis-impaired drivers during routine daytime activities, citing trust and familiarity, with safety concerns developing only in young adulthood.
Longitudinal study of 2,745 Canadian workers found cannabis use at work nearly doubled injury risk, while off-the-job use showed no increased risk.
Study of 2,095 older drivers found cannabis users had 58% more traffic stops but no significant increase in crashes, possibly because they rarely drove after use.
Five-year Italian DUI study found 55% of cannabis-positive drivers only had inactive metabolites in blood — delayed testing couldn't confirm recent use or impairment at time of driving.
Cannabis users accurately predicted their driving impairment after THC inhalation — self-rated confidence correlated with actual simulator performance and THC dose.
National survey data from 2016-2020 found that cannabis-impaired driving among users actually decreased even as past-year cannabis use rose 29%, while alcohol-impaired driving also continued to decline.
Cannabis-involved traffic injury ER visits in Ontario rose 475% from 2010-2021, accelerating after retail expansion, though they remained rare at 0.04% of all traffic injury visits.
Rome study found drivers with cannabis urinary markers had 8x higher crash odds even when blood THC was below 1 ng/mL.
Study of 31 cannabis users found significant visual impairment after use but no compensatory speed reduction.
National survey found 6.3% of US drivers aged 16-20 reported driving after cannabis use, more than double the alcohol DUI rate of 2.6%.
Tablet-based cognitive test battery detected acute cannabis impairment, with occasional users showing larger deficits than daily users across four cognitive domains.
Interrupted time series analysis found Washington State traffic crashes increased after marijuana legalization and especially after retail store openings.
Systematic review finds roadside cannabis screening devices detect THC presence but struggle to reliably indicate impairment, highlighting a key legalization challenge.
Ontario data showed cannabis was the most common substance (52.8%) in suspected impaired drivers from 2008-2019, with 80% of cases involving multiple drugs.
Adding Finger-to-Nose test and head movement observations to the standard sobriety test improved cannabis impairment detection from 67% to 88% sensitivity.
Review of 70 studies found attitudes toward cannabis-impaired driving are mostly negative but mixed, with youth and frequent users more favorable and perceived enforcement risk low.
Occasional cannabis users showed impaired reaction time and memory after smoking, while daily users showed tolerance to these effects but still took longer on a driving-related decision task without losing accuracy.
Multi-site ED study found cannabis use alone was not linked to higher crash risk, while alcohol alone and alcohol-cannabis combined both increased motor vehicle collision odds, with high cannabis use paradoxically associated with lower crash risk.
Survey of 69,621 Canadian students found nearly half of dual alcohol-cannabis users reported impaired driving or riding exposure, with 9.5 times higher odds than alcohol-only users.
Annual Washington State surveys found young adult cannabis-impaired driving stayed at about 12.5% through the COVID pandemic, with no significant change from pre-pandemic trends.
A study of 1,941 Washington State young adults found peer approval of driving after combined alcohol and cannabis use predicted impaired driving behavior more than perceived prevalence.
Five years after Washington opened cannabis retail stores, alcohol DUI decreased and cannabis DUI held steady overall (11%) while dropping among cannabis users.
A survey of 1,467 young Canadian cannabis users found that male sex, frequent use, and peer driving norms most strongly predicted seeing cannabis-impaired driving as low risk.
Analysis of 299 Israeli news articles found recreational cannabis-impaired driving was framed with individual blame and enforcement, while medical cannabis driving received more sympathetic, educational framing.
Survey of 200 cannabis users found that dependence, emotional dysregulation, and psychopathology predicted other substance use and impaired driving, with no difference between medicinal and black-market users.
A systematic review found THC acutely impairs eye movement control and chronic cannabis users show lasting visual scanning deficits, with potential for roadside impairment testing.
Cannabis users showed reduced demand when imagining driving but increased demand in sleep contexts with cannabis cues, suggesting safety concerns can override drug motivation.
After controlled THC dosing, cannabis users who felt unsafe to drive showed more impairment — but some who felt safe were still impaired, especially experienced users.
Randomized trial found nabiximols for tic disorders did not impair driving and improved it in 42% of patients who were initially unfit to drive.
A web-based tool for teen drivers addressing cannabis and alcohol impaired driving showed strong acceptability in early testing, with nearly all participants finding it helpful.
Switzerland's 2022 medical cannabis deregulation conflicts with zero-tolerance THC driving laws, creating legal uncertainty for prescribed patients.
Analysis of US state cannabis policies over 27 years found permissive laws linked to fewer traffic deaths, while pharmaceutical-style regulations were linked to more.
Nearly 9,000 Wisconsin DUI cases show average blood draw delay of 1.8 hours — long enough for THC levels to drop below legal limits, especially after severe crashes.
Testing of four roadside oral fluid THC devices in nearly 9,000 samples found massive performance differences. Only one device (Drager DrugTest) achieved over 96% accuracy.
CDC analysis of national survey data found marijuana-impaired driving increased from 4.5% to 5.3% of US drivers between 2016 and 2019, while alcohol-impaired driving declined.
Crossover trial found no meaningful next-day impairment in cognition, psychomotor function, or simulated driving after adults with insomnia took 10mg THC + 200mg CBD oil the previous evening.
Trial found oral fluid THC tests were mostly negative just 30 minutes after oral medicinal cannabis (poor sensitivity) and completely negative by 10 and 18 hours, suggesting low next-morning detection risk.
Italian study of 335 impaired driving recidivists found polydrug use doubled recidivism risk, with the cocaine-cannabis combination specifically flagged as a risk factor.
Controlled study found eyelid tremor had only 18% specificity for detecting recent cannabis use, with trained experts unable to reliably distinguish users from non-users.
Analysis of Canada's National Cannabis Survey found cannabis-impaired driving spiked significantly in rural areas right after legalization but returned to baseline within a year.
First study of cannabis edibles and driving found minimal objective impairment (brief speed decrease at 2 hours) despite 7 hours of subjective intoxication and blood THC of ~2.8 ng/mL.
Analysis of 683,000 US trauma center MVC drivers found cannabis-positive results rose from 10.2% to 14.6% between 2017-2020, with the steepest increase among adolescents.
Rigorous causal analysis found recreational cannabis legalization increased traffic fatalities in US states, with the effect primarily linked to the start of retail sales.
Connecticut crash-toxicology data linkage found alcohol, cannabis, and other drugs significantly predicted driver injury, with lack of safety equipment as the strongest predictor.
Survey of over 4,000 California cannabis users found mixed awareness of driving regulations six years after legalization, with lower knowledge linked to worse driving outcomes.
Systematic review found 10 of 12 studies showed no linear relationship between blood THC levels and driving performance, questioning THC-based impairment testing.
Study of 1,847 young adults found some cannabis retail laws (billboard bans, driving warnings) achieved intended effects while many others showed no measurable impact.
Latent class analysis of 4,031 young adults found moderate oil/concentrate users had the worst outcomes across problematic use, mental health, and impaired driving measures.
Proof-of-concept study found THC appeared in breath after eating cannabis edibles, but timing and magnitude varied widely across 29 participants.
Driving simulator study of 118 participants found occasional cannabis users had more lane departures after use, while daily users (including concentrate users) showed minimal changes, suggesting tolerance plays a major role.
Pupillometer study of 126 participants found diminished pupil dynamics (light response and recovery) were moderately predictive of recent cannabis use, with AUC of 0.73-0.75.
Blood tests from 8,328 injured Canadian drivers found 54.9% positive for at least one substance — THC was the most common drug detected after alcohol in this post-legalization dataset.
In a 30-person crossover RCT, THC-related simulator crashes peaked 4 hours after inhalation.
National survey found 20.6% of cannabis users reported DUI versus 8.6% of alcohol users, with substance disorders, early initiation, and age 65+ as risk factors.
Systematic review found 15 Canadian youth DUIC prevention initiatives since legalization, but limited evidence that any changed actual driving behavior.
Pilot RCT of a smartphone app for youth cannabis-impaired driving showed positive reception and preliminary efficacy, but faced significant recruitment and retention challenges.
Nearly half of regular cannabis users exceeded zero-tolerance driving THC limits after 48+ hours of abstinence, raising questions about per se impairment laws.
Survey of 979 cannabis users found 23% drove within 2 hours of use, with males, frequent users, and medical cannabis patients at higher risk.
Analysis of 6,210 traffic-stop blood samples in Munich found cannabis was the top substance detected (66-67%) throughout the pandemic, with THC metabolite levels rising during lockdowns.
Survey of 1,030 German cannabis patients found flower users consumed an average of 336 mg THC daily, nearly 20x more than those using other preparations, with implications for driving safety.
Meta-analysis of 31 studies found cannabis use associated with 55% higher fatal crash risk and doubled injury crash risk, with low certainty evidence per GRADE.
A placebo-controlled trial found THC caused pupil constriction (not dilation) and dampened the pupillary light reflex for at least 5 hours in cannabis-naive volunteers.
Five years post-legalization in Canada, overall driving after cannabis use rose, but among consumers specifically, it slightly declined.
Cannabis driving laws are being set without adequate science—we need comprehensive THC pharmacokinetic data to connect blood levels to actual impairment.
A pharmacokinetic model showed that current blood THC limits for driving (1, 2, or 5 ng/mL) may be unreliable for people who consume cannabis orally, with the 1 ng/mL limit most prone to false positives.
Analysis of 740 cannabis driving cases in Germany found THC blood levels were too weakly correlated with impairment to define a useful legal threshold, and the new 3.5 ng/mL limit would remove one-third of current offenses.
A metabolomics study identified blood markers that distinguished cannabis intoxication from mere use with 80% accuracy, potentially solving the problem of detecting actual impairment rather than just consumption.
Survey of 385 Australian cannabis users found 21.5% drove within 3 hours of use, with heavy users and those unconcerned about testing most likely to drive soon after consuming.
Randomized simulator trial finds cannabis impairs driving performance even when users feel capable, highlighting a dangerous perception gap.
Medicinal cannabis users showed no hazard perception decline after oral THC and drove more cautiously, but none could accurately judge their own impairment level.
A Quebec study found that higher cannabis sales were linked to 12% more drug-related and 12% more alcohol-related traffic crashes across five cities, with Montreal showing 87-93% increases.
THC was detected in 12.4% of crash victims—nearly as common as alcohol—and unlike alcohol, drivers weren't less likely to test positive than passengers.
Analysis of 35 impaired driving cases found THC levels sometimes rose at later blood draws, showing the difficulty of determining when cannabis was last used.
Among 3,050 New Zealand drunk drivers, 27% also tested positive for cannabis and 16% for prescription medications, revealing widespread poly-substance use among impaired drivers.
Latent class analysis of 563 German cannabis-using drivers identified three distinct risk profiles: low risk (48%), DUIC-specific risk (30%), and global risk (22%), suggesting tailored prevention approaches are needed.
Prospective study of 10,322 injured drivers at 17 Canadian trauma centers found alcohol increased hospital admissions after crashes, but THC did not modify this effect or independently predict injury severity.
Case report of a 28-year-old with Tourette syndrome and ADHD found medical cannabis treatment did not impair driving fitness, contributing to evidence on tolerance and driving safety.
Study identified distinct subgroups of cannabis users based on how they assess impairment risk, monitor their use, and plan safe transportation, revealing heterogeneity that one-size-fits-all policies miss.
Driving simulator study of 88 adults showing edible cannabis impairs driving performance, with effects varying by usage frequency and driving environment.
EMA study of 88 co-users finding that simultaneous alcohol and cannabis use paradoxically increases both perceived impairment and willingness to drive.
Protocol for the first real-world on-track driving study testing whether medical cannabis patients are impaired at therapeutic doses, compared to alcohol at the legal driving limit.
Canadian impaired driving reports rose after 2018 cannabis legalization, but analysis suggests enhanced police enforcement and pandemic effects drove the increase more than cannabis sales themselves.
JAMA-published trial of 183 cannabis users shows a portable brain scanner (fNIRS) detects THC impairment with 90% accuracy vs. 69% for field sobriety tests, with far fewer false positives.
National survey finds 1 in 5 older adults who use cannabis drive within 2 hours of consumption, with daily users, men, and those using for mental health at highest risk.
Survey of 5,167 university students across 6 countries found significant cross-national differences in how dangerous cannabis and alcohol impaired driving are perceived, with implications for targeted prevention.
Experiment with 686 cannabis-using drivers found that detailed health messages about cannabis-impaired driving risks accidentally increased intentions to drive high by making people feel capable of managing the risk.
Analysis of 10,517 MVC trauma patients over 16 years found significant increases in marijuana-positive drivers after Pennsylvania's medical marijuana legalization, with these patients having longer hospital stays.
Review confirms THC impairs driving for 4-5 hours, CBD does not impair driving, and alcohol plus cannabis amplifies the effect.
Behavioral economics study finds cannabis demand decreases as driving becomes more imminent, and risk perception influences consumption levels.
Decade of US crash data shows stronger alcohol and cannabis policies each independently reduce substance-involved motor vehicle deaths.
Review argues that older adults may be more impaired by cannabis while driving due to age-related changes in metabolism, cognition, and the endocannabinoid system.
Study of 1,247 young parents finds single mothers use cannabis most frequently for coping, while educated fathers have the most consequences and driving under the influence.
THC at concentrations found in the blood of traffic accident drivers caused dose-dependent neurotoxicity in human neuronal cells, including oxidative stress, mitochondrial damage, and early cell death signals.
A Lancet study comparing Germany and Austria found no significant increases in cannabis use or stoned driving 8 months after German legalization, though 21.5% of driving-under-influence episodes combined cannabis with alcohol or other drugs.
Analysis of 48,058 German traffic cases found the new 3.5 ng/mL THC limit poorly separates impaired from unimpaired drivers, with identical median THC in both groups.